30 closest matches · ranked by relevance
Myelodysplastic Syndromes · Thrombocytopenia
Primary: Number of Participants With Response Between Weeks 16 and 20 — 11 Participants
Myelodysplastic Syndrome
Primary: Number of Participants With Response — 2; 2; 4; 6 participants
Myelodysplastic Syndrome · MDS
Primary: Number of Participants With Erythroid Response — 5 participants
Myelodysplastic Syndrome
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days — 30.8; 11.9 Percentage of Participants — p=0.0005
MDS
Primary: Percentage of Participants With at Least One Red Blood Cell (RBC) Transfusion During the Double-blind Treatment Period — 59.2; 36.1 percentage of participants — p=0.008
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Primary: PK Phase: Area-under-the Concentration-time Curve (AUC0-24) for Lenalidomide — 817 ng*h/mL
Myelodysplastic Syndrome
Primary: Dosage Determination for IV-infusion of Vosaroxin in Int-2 or High-risk Mds — 200 mg/m^2
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days) — 3; 20; 23 Participants — p=<0.001
Anemia
Primary: Percentage of Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for ≥ 56 Days as Determined by an Independent Review Committee (IRC) — 2.5; 26.9…
Leukemia, Myeloid, Acute · Myelodysplastic Syndromes
Primary: Phase I: Maximum Tolerated Dose (MTD) of LBH589 When Given in Combination With Decitabine — 40 mg (level 5b dosing schedule)
Myelodysplastic Syndromes
Primary: Participants Who Achieved Red Blood Cell (RBC) -Transfusion Independence — 59 participants
Leukemia · Leukemia, Myeloid · Monocytic Leukemia
Primary: Clinical Response: Hematological Improvement - Erythroid (HI-E) — 0; 0 participants
Myelodysplastic Syndromes
Primary: Hematologic Improvement of Platelets (HI-P) After 4 Months on Therapy — 71.75; 18.75 platelets (/nL)
Myelodysplastic Syndromes
Primary: Number of Participants With Confirmed Responses (Complete Remission, Partial Remission, or Hematologic Improvement) as Defined by the International Working Group…
Myelodysplastic Syndromes
Primary: Percentage of Participants With Clinical Response as Measured by the International Working Group (IWG) Criteria for Hematological Improvement — 50.00; 71.43; 100.00…
Myelodysplastic Syndromes
Primary: Percentage Of Participants Who Achieved Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 Weeks From Week 1 to Week 24 — 37.91; 13.16 Percent of Participants…
Myelodysplastic Syndrome
Primary: One Year Overall Survival of Allogeneic Transplant Recipients After Transplantation — 50 percentage of participants
Leukemia
Primary: Number of Dose Limiting Toxicities for Determining Maximum Tolerated Dose (MTD) of Lenalidomide in Combination With 5-azacytidine (5-AZA) — 0; 0; 0; 0 participants
Myelodysplastic Syndrome
Primary: The Overall Improvement Rate — 23.3; 22.7; 16.3; 0 Percentage of Participants
Acute Myelogenous Leukemia · Myelodysplastic Syndrome
Primary: Number of Participants With a Response (Complete Remissions (CR), Complete Remissions With Incomplete Platelet Recovery [CRp] and Partial Responses) — 1; 1; 0 participants
Leukemia
Primary: Overall Response (OR) — 3 Participants
Anemia · Myelodysplastic Syndromes · Chronic Myelomonocytic Leukemia
Primary: Percentage of Participants With Erythroid Hematological Improvement (HI-E) Starting Before the Completion of Five Cycles of Treatment (Responder Rate) — 0; 66.7; 42.9…
Myelodysplastic Syndrome
Primary: Response Signature in Transfusion Dependent MDS Patients — 24; 1; 17; 6 Participants
MDS · Myelodysplastic Syndromes · Thrombocytopenia
Primary: Occurrence of a Clinically Significant Thrombocytopenic Event — 11; 8; 10; 11 Participants
Adult Myelodysplastic Syndrome · Anemia · Chronic Myelomonocytic Leukemia
Primary: Number of Patients Demonstrating Overall Hematologic Improvement (HI) — 6; 5; 7 Participants
Myelodysplastic Syndromes
Primary: Number of Patients Who Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 0 Participants
Leukemia · Myelodysplastic Syndromes
Primary: PHASE I: Maximum Tolerated Dose of Azacitidine — 75 mg/m2 subcutaneously for 5 days
Low and Int 1-risk Myelodysplastic Syndrome
Primary: Difference in Percentage of Patients Achieving Erythroid Response Within 12 Weeks, by Treatment Group (Full Analysis Set) — 41.7; 27.3 percentage of participants
Leukemia · Myeloproliferative Diseases
Primary: Number of Participants With Complete Response (CR) — 19 Participants
Myelodysplastic Syndromes
Primary: Response to Treatment - Hematologic Improvement or Complete Response — 21 Participants